BioCentury

1:19 AM GMT, Mar 28, 2007
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Top Story

FDA posts Provenge documents

Data submitted by Dendreon (DNDN) on Provenge sipuleucel-T "tend to support a finding of clinically meaningful increased survival, but doubts remain about the persuasiveness of the efficacy data,"

Read the full 280 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.